Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Pharma Tech

Affinia Therapeutics receives FDA orphan drug designation for AFTX-201

Jul 23, 2026, 9:39 AM

Read Full Article → Affinia Therapeutics receives FDA orphan drug designation for AFTX-201

Affinia Therapeutics receives FDA orphan drug designation for AFTX-201

Translate article text

Choose a language and wait for the translated text.

Affinia Therapeutics has received FDA orphan drug designation for AFTX-201, a treatment in development for BAG3-associated DCM.

Affinia Therapeutics receives FDA orphan drug designation for AFTX-201 | PharmaVoice